ArticleCancer causes & control : CCC2026
Global burden of prostate cancer (1990-2021) from Brazil: trends in disability-adjusted life years, incidence, mortality, and prevalence.
Article in Cancer causes & control : CCC, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProstate cancer remains a significant public health challenge globally, with marked regional disparities in Brazil linked to demographic, socioeconomic, and healthcare access factors. This study analyzed trends in disability-adjusted life years (DALYs), incidence, mortality, and prevalence of prostate cancer across Brazilian macroregions (1990-2021) using data from the Global Burden of Disease (GBD) database. Joinpoint regression was employed to identify temporal trends and average annual percentage changes (AAPCs), stratified by age and region.
methodsData were extracted from GBD 2021, encompassing national and regional estimates. Statistical analyses included age-standardized rates, AAPC calculations, and pairwise comparisons to assess parallelism in trends.
resultsResults revealed substantial regional disparities: Southern and Southeastern regions exhibited the highest DALYs, incidence, and prevalence, patterns that are consistent with better diagnostic infrastructure and aging populations. In contrast, Northern regions showed lower rates but the steepest AAPC increases (e.g., incidence: + 2.59% annually in age group 70-74), suggestive of improving yet insufficient healthcare access. Mortality declined in the South and Southeast (AAPC up to -0.70% in age group 70-74) due to therapeutic advances but rose in the Northeast (AAPC up to + 0.76% in age group 65-69). Prevalence surged nationwide, peaking in older age groups (e.g., 2,619.50 cases/100,000 men in Southern 70-74 age group), indicating prolonged survival. Joinpoint analyses identified non-linear trends, with incidence stabilizing post-2010 following shifts in screening guidelines.
conclusionThese findings underscore the need for region-specific policies to address inequities in cancer care, enhance early diagnosis, and optimize resource allocation. Strengthening healthcare infrastructure in underserved regions and targeted screening for younger high-risk populations are critical to mitigating Brazil's prostate cancer burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.